1. Volume 199, Issue 5, Pages 1129-1142 (May 2018)
Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma 
Arlene O. Siefker-Radtke, Andrea B. Apolo, Trinity J. Bivalacqua, Philippe E. Spiess, Peter C. Black 
The Journal of Urology 
Volume 199, Issue 5, Pages (May 2018)
DOI: /j.juro
Copyright © 2018 American Urological Association Education and Research, Inc. Terms and Conditions

2. Figure 1
Basal and luminal subtypes of MIBCs. PPARG, peroxisome proliferator-activated receptor γ. ESR1, estrogen receptor 1. STAT3, signal transducer and activator of transcription 3. TP63, tumor protein 63.
Reprinted by permission from: Choi W et al: Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol 2015; 11: 400.
The Journal of Urology  , DOI: ( /j.juro )
Copyright © 2018 American Urological Association Education and Research, Inc. Terms and Conditions

3. Figure 2
Urothelial carcinoma specific antitumor immunity cycle and role of CTLA-4 and PD-1/PD-L1 pathways. MHC-I, major histocompatibility complex class I. TCR, T-cell receptor.
Adapted with permission from: Kim JW et al: Emerging immunotherapies for bladder cancer. Curr Opin Oncol 2015; 27: 191.
The Journal of Urology  , DOI: ( /j.juro )
Copyright © 2018 American Urological Association Education and Research, Inc. Terms and Conditions